In the month of February, which is dedicated to raising awareness about ovarian cancer, Cleo Diagnostics (ASX:COV) is emphasizing the critical and pressing need for earlier and more precise detection methods for this serious disease that impacts countless women.
Ovarian cancer poses a significant challenge when it comes to early diagnosis due to its often ambiguous symptoms that can easily be mistaken for minor ailments. This difficulty is further complicated by the absence of a reliable diagnostic test; confirmation of ovarian cancer usually requires invasive surgical procedures. Consequently, many women find out they have the disease only after it has advanced, which severely restricts their treatment options and leads to poorer health outcomes.
The consequences of not diagnosing this cancer promptly are alarming. Over fifty percent of women diagnosed with ovarian cancer succumb to the illness within five years, showcasing a mortality rate that is over six times greater than that of breast cancer, where the five-year survival rate hovers around eight percent. These statistics highlight the significant unmet needs in clinical care and the urgent necessity for innovative approaches in diagnostic processes.
Cleo Diagnostics aims to bridge this gap with the creation of a straightforward blood test that is designed to facilitate earlier evaluations of ovarian cancer, thereby enhancing health outcomes for women around the globe. This groundbreaking test is founded on more than 15 years of dedicated research and development, focused on the identification of a new biomarker known as CXCL10, which has shown to outperform current diagnostic standards. The company is making strides toward entering its first commercial market, with plans to submit to the US Food and Drug Administration later this year.
Dayna Louca, the Head of Corporate Development at Cleo Diagnostics, emphasized the importance of Ovarian Cancer Awareness Month as a crucial reminder of the hurdles faced in early detection and the vital role that diagnostics play in improving survival rates.
She expressed Cleo's belief that their innovative ovarian cancer blood test could fundamentally transform the landscape of detection, enabling earlier diagnoses and ultimately leading to better health outcomes for women worldwide.
